In response to this extraordinary pandemic, worldwide research institutes are sprinting to find effective drugs or potential vaccines for COVID-19. In February 2020, the World Health Organization (WHO) named it coronavirus disease-19 (COVID-19) officially, then it declared a pandemic on Ma(World Health Organization 2020).īy the 3rd of May, 2021, the total number of cases diagnosed with COVID-19 in the world exceeded 153 million, while the total number of recovered cases was more than 131 million, whereas more than 3,200,000 deaths were reported (Coronavirus Update (Live): - Worldometer, 2021). On January 7, the Chinese Centers for Disease Control and Prevention (CDC) announced that a novel coronavirus was identified after whole-genome sequencing of throat swabs and samples obtained from the lower respiratory tract of patients (Zhu et al. First, an unknown pneumonia case was detected in Wuhan, province of Hubei in China on December 12, 2019, then a frequent number of cases complained of the related symptoms of dry cough, fever, shortness of breath, and fatigue, that quickly progressed into pneumonia ending up with acute respiratory distress syndrome (ARDS) in 5% of the patients (Chen et al. Since the early days of 2020, the world is gripped by a COVID-19 pandemic caused by the highly contagious acute respiratory syndrome coronavirus 2 (SARS CoV-2). We tested also some other drugs falling under the scope of investigation regarding interference with a degree of severity of COVID-19 like angiotensin II blockers used as antihypertensive, and our study suggests a therapeutic rather than predisposing effect of these drugs against COVID-19. Other OTC drugs widely used and tested in our study are heartburn drugs and they show no significant binding. Another category of tested drugs is oral antiseptics of mouth rinsing solutions that unexpectedly exhibited significant affinity to the target proteins employed by the virus for attachment and cell internalization. Three antibiotics in our screening polymyxin B, bafilomycin A, and rifampicin show motivating binding stability with more than one target of the virus. In this study, we virtually screened a library of FDA-approved drugs prescribed for different therapeutic purposes against versatile COVID-19 specific proteins which are crucial for the virus life cycle. A shortcut to this delicate pathway is computational-based analysis of FDA-approved drugs against assigned molecular targets of the coronavirus. Development of vaccines or new drugs against COVID-19 comprises several stages of investigation including efficacy, safety, and approval studies. Coronavirus disease (COVID-19) is an emerging pandemic that threatens the world since the early days of 2020.
0 kommentar(er)
